TABLE 4.
Pharmacokinetic parameters and analysis for dihydroartemisinin and piperaquine following administration of dihydroartemisinin-piperaquine with or without tafenoquinea
| Analyte and treatment group or parameter | Geometric mean AUC0–τ (ng · h/ml) | Geometric mean AUC0–last (ng · h/ml) | Geometric mean Cmax (ng/ml) | Geometric mean t1/2 (h) | Median Tmax (h) (range) |
|---|---|---|---|---|---|
| Dihydroartemisinin | |||||
| TQ + DHA-PQP (n = 24) | 761.2 | 748.9 | 262.5 | 1.7 | 2.0 (1.0–6.0) |
| DHA-PQP (n = 23) | 758.0 | 749.5 | 277.5 | 1.6 | 2.0 (1.0–6.0) |
| CVb (%) | 44.0 | 43.9 | 50.9 | 36.7 | |
| Ratio (90% CI) | 1.00 (0.82, 1.24) | 1.00 (0.81, 1.23) | 0.95 (0.75, 1.20) | 1.05 (0.88, 1.25) | |
| Piperaquine | |||||
| TQ + DHA-PQP (n = 24) | 9,206.5 | 35,660.1 | 840.5 | 360.4 | 4.0 (3.0–8.0) |
| DHA-PQP (n = 23) | 9,815.6 | 37,358.0 | 928.2 | 382.2 | 4.0 (3.0–8.0) |
| CVb (%) | 30.2 | 32.5 | 36.8 | 89.5 | |
| Ratio (90% CI) | 0.94 (0.81, 1.08) | 0.95 (0.82, 1.11) | 0.91 (0.76, 1.08) | 0.94 (0.65, 1.37) |
a
CVb, between-subject variability.